Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Myriad Genetics, Inc.    MYGN

MYRIAD GENETICS, INC. (MYGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies

Near a solid support area

share with twitter share with LinkedIn share with facebook
share via e-mail
02/19/2013 | 03:00pm

Myriad Genetics' share price was heavily penalized and is now in an oversold situation near to a solid support area.

Myriad Genetics is technically oversold and is near to the USD 24.2 support. This situation gives credit to a potential technical rebound. Thus, the stock could find new energy and would rise towards the next USD 26.1 resistance.

So as to make the most of a potential technical rebound of Myriad Genetics, it seems opportune to take a long position at the current price. A confirmation of this pattern would enable the security to reach the USD 27.62 resistance, with a potential gain of 13.2 %. Investors should not insist under USD 24.19 and place a stop loss order under this threshold.


© Zonebourse.com 2013
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 770 M
EBIT 2018 94,2 M
Net income 2018 63,5 M
Finance 2018 18,1 M
Yield 2018 -
P/E ratio 2018 35,33
P/E ratio 2019 49,26
EV / Sales 2018 3,01x
EV / Sales 2019 2,81x
Capitalization 2 336 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart MYRIAD GENETICS, INC.
Duration : Period : Day
Myriad Genetics, Inc. Technical Analysis Chart | MYGN | US62855J1043 | 4-Traders
Duration : Period : Week
Myriad Genetics, Inc. Technical Analysis Chart | MYGN | US62855J1043 | 4-Traders